Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
doi 10.19106/jmedsci004802201606
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Related search

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus

Frontiers in Pharmacology
Pharmacology
2017English

Dipeptidyl Peptidase-4 (DPP-4; CD26)

Science-Business eXchange
2014English

Incretin Mimetics and Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes

European Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2007English

Acquired Hemophilia a Associated With Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Single-Center Case Series in Japan

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus

2011English

Need for Streamlined Use of DPP-4 Inhibitors in the Treatment of Type 2 Diabetes

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2016English

Emerging DPP-4 Inhibitors: Focus on Linagliptin for Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2013English

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2014English

Limited Extent of Pleiotropic Effects Mediated by Dipeptidyl Peptidase-4 Inhibitors in Patients With Diabetes Mellitus

Circulation Journal
MedicineCardiovascular MedicineCardiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy